Based on the empirically established role of GH in cancer progression [10,13,14,21,23,76], our findings reveal that elevated tumoral GHR expression in NSCLC is associated with the upregulation of gene signatures involved in key oncogenic processes. The gene discussed is GH1; the disease is non-small cell lung carcinoma.